1013 DIFFERENT EFFECT BETWEEN RENIN-ANGIOTENSIN SYSTEM INHIBITORS AND CALCIUM CHANNEL BLOCKERS IN HYPERTENSIVE PATIENTS

Abstract

Purpose: Characteristics of hypertensive patients treated with renin-angiotensin system inhibitors (RASIs) and calcium channel blockers (CCBs) were investigated. Methods: Hypertensive patients under a monotherapy with RASIs (n = 175, RASIs group) or CCBs (n = 261, CCBs group) were recruited from 9,288 participants in our health checkup program. Their brachial blood pressure (BP), central BP (CBP), electrocardiogram (ECG) voltage (SV1+RV5), estimated glomerular filtration rate (eGFR), urinary excretion of albumin (expressed as the ratio of urine albumin to creatinine), and lipid profiles were evaluated. Untreated hypertensive patients (n = 671, no medication group) were used as a reference. Patients treated with anti-diabetic or anti-dyslipidemic medication were excluded from the study. Results: Brachial BP and CBP were similarly reduced in the RASIs and CCBs groups. In contrast, the urine albumin level was lower in the RASIs than in the CCBs group. Beneficial effects on lipid profiles were observed in the RASIs group (Table). Conclusions: RASIs reduces urinary excretion of albumin and, thus, may prevent the development of chronic kidney disease and cardiovascular disease.*p < 0.05 vs. “No medication group”, †p < 0.05 vs. “RASIs group” by Scheffe test (ANOVA)